Genetically engineered Newcastle disease virus for malignant melanoma therapy

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 796-804

  Zamarin, D ^a,b   Vigil, A ^a,c   Kelly, K ^b   Garcia Sastre A ^a   Fong, Y ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOLYTIC NEWCASTLE DISEASE PARAMYXOVIRUS B1; ONCOLYTIC NEWCASTLE DISEASE PARAMYXOVIRUS F3AA; ONCOLYTIC NEWCASTLE DISEASE PARAMYXOVIRUS F3AA INTERLEUKIN 2 FUSION PROTEIN; ONCOLYTIC PARAMYXOVIRUS; UNCLASSIFIED DRUG; VIROTHERAPY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, ISOGENEIC; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

ANIMALIA; MURINAE; MUS; NEWCASTLE DISEASE VIRUS;

EID: 67349132360     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.14     Document Type: Article

References (50)

1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A et al. Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82: 364-380.
2. Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther 2007; 7: 701-713.
3. Alexander DJ. Newcastle Disease, Newcastle Disease Virus - An Avian Paramyxovirus. Kluwer Academic Publishers: Dordrecht, The Netherlands, 1988; pp 1-22.
4. Seal BS, King DJ, Sellers HS. The avian response to Newcastle disease virus. Dev Comp Immunol 2000; 24: 257-268.
5. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448-453.
6. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 1994; 86: 1228-1233.
7. Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z. The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol 1995; 121: 169-174.
8. Cassel WA, Murray DR. Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul 1988; 7: 351-352.
9. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992; 9: 169-171.
10. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77; discussion 77-79.
11. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004; 67: 83-93.
12. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1999; 19: 635-638.
13. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266.
14. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228.
15. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193 1007-1008.
16. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420-4425.
17. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.
18. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
19. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007; 67: 8285-8292.
20. Poste G, Doll J, Hart IR, Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980; 40: 1636-1644.
21. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-5868.
22. Entin I, Plotnikov A, Korenstein R, Keisari Y. Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy. Clin Cancer Res 2003; 9: 3190-3197.
23. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9: 289-295.
24. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61: 1095-1099.
25. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613-631.
26. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3 999-1005.
27. Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 2005; 14: 885-892.
28. Prince AM, Ginsberg HS. Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus-cell interaction. J Immunol 1957; 79: 94-106.
29. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): Brief history of its oncolytic strains. J Clin Virol 2000; 16: 1-15.
30. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80: 5145-5155.
31. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77: 9522-9532.
32. Fabian Z, Csatary CM, Szeberenyi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007; 81: 2817-2830.
33. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004; 64: 8057-8061.
34. Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 2003; 9: 495-498.
35. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619-627.
36. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002; 21: 85-93.
37. Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677-696.
38. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Therapy 1999; 6: 63-73.
39. Haas C, Ertel C, Gerhards R, Schirrmacher V. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. Int J Oncol 1998; 13: 1105-1115.
40. Hrabak A, Csuka I, Bajor T, Csatary LK. The cytotoxic antitumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro. Cancer Lett 2006; 231: 279-289.
41. Aydin N, Jack A, Montenegro G, Boyes C, Alam K, Wallack MK. Expression of melanoma-associated antigens in human dendritic cells pulsed with an interleukin-2 gene encoded vaccinia melanoma oncolysate (rIL-2VMO). Cancer Biol Ther 2006; 5: 1654-1657.
42. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc Natl Acad Sci USA 2006; 103: 8203-8208.
43. de Leeuw OS, Koch G, Hartog L, Ravenshorst N, Peeters BP. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J Gen Virol 2005; 86: 1759-1769.
44. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999; 73 5001-5009.
45. Shin EJ, Chang JI, Choi B, Wanna G, Ebert O, Genden EM et al. Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg 2007; 136: 811-817.
46. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol 2001; 75: 11868-11873.
47. Engel-Herbert I, Werner O, Teifke JP, Mebatsion T, Mettenleiter TC, Romer-Oberdorfer A. Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein. J Virol Methods 2003; 108: 19-28.
48. Schirrmacher V. In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination. Int J Oncol 1999; 15: 217-227.
49. Vigil A, Martinez O, Chua MA, Garcia-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 2008; 16: 1883-1890.
50. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 2007; 13: 977-985.